{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T13:43:23Z","timestamp":1770471803649,"version":"3.49.0"},"reference-count":15,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,5,6]],"date-time":"2004-05-06T00:00:00Z","timestamp":1083801600000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2004,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The tumor necrosis factor \u03b1 (TNF\u03b1) inhibitors etanercept and infliximab have shown good clinical results in the treatment of rheumatoid arthritis and other autoimmune disorders. With these novel fusion proteins, immune\u2010mediated side effects, among them various cutaneous reactions, have been encountered. We report herein the case of an erythema multiforme\u2013like skin reaction to treatment with the monoclonal anti\u2010TNF\u03b1 antibody adalimumab in a patient with rheumatoid arthritis. The reaction occurred after the sixth injection and affected the palms and soles as well as the injection site. Discontinuation of the adalimumab therapy resulted in rapid improvement of the condition. Although this patient was receiving concomitant immunomodulatory therapy with methotrexate and leflunomide, these medications were not discontinued when the reaction developed, and no other potential pathogenetic mechanisms were identified. We believe the reaction is most likely attributable to adalimumab.<\/jats:p>","DOI":"10.1002\/art.20155","type":"journal-article","created":{"date-parts":[[2004,5,6]],"date-time":"2004-05-06T20:04:33Z","timestamp":1083873873000},"page":"1690-1692","source":"Crossref","is-referenced-by-count":83,"title":["Skin reaction to adalimumab"],"prefix":"10.1002","volume":"50","author":[{"given":"W.","family":"Beuthien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.\u2010U.","family":"Mellinghoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"von Kempis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,5,6]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.8.1019"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10697"},{"key":"e_1_2_4_4_2","first-page":"893","article-title":"Clinical, histological and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor \u03b1 receptor:Fc fusion protein","volume":"137","author":"Zeltser R","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_4_5_2","first-page":"2041","article-title":"Leukocytoclastic vasculitis due to etanercept","volume":"27","author":"Galaria NA","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-8-199910190-00031"},{"key":"e_1_2_4_7_2","volume-title":"Remicade (infliximab) prescribing information","year":"2003"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000069965"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10348"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.9.1258"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400401"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432202"},{"key":"e_1_2_4_13_2","first-page":"175","article-title":"Two cases of etanercept\u2010induced systemic lupus erythematosus in patients with rheumatoid arthritis","volume":"60","author":"DeBrandt MJ","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07714-0"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000372-199704000-00005"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.2.133"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.20155","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.20155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T13:32:58Z","timestamp":1696944778000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.20155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["10.1002\/art.20155"],"URL":"https:\/\/doi.org\/10.1002\/art.20155","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}